REFERENCES:

Aapro MS. Neoadjuvant therapy in breast cancer: Can we define its role? Oncologist 2001;6 Suppl 3:36-9. Abstract

Akashi-Tanaka S et al. Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy. Int J Cancer 2001;96:66-73. Abstract

Buchholtz TA et al. Decrease in bcl-2 expression shortly after neoadjuvant chemotherapy predicts primary breast cancer response to treatment. Breast Cancer Res Treat 2001;Abstract 231.

Burstein HJ et al. Preoperative trastuzumab (T) and paclitaxel (P) for HER2 overexpressing (HER2+) stage II/III breast cancer: Clinical, pathological and serological findings. Breast Cancer Res Treat 2001; Abstract 507.

Carey LA et al. Disproportionate CNS relapse after aggressive neoadjuvant chemotherapy. Breast Cancer Res Treat 2001;Abstract 511.

Colleoni M et al. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol 2001;19:4141-9. Abstract

El-Didi MH et al. Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management. Surg Today 2000;30:249-54. Abstract

Esserman LJ et al. Response to neoadjuvant therapy for breast cancer by magnetic resonance imaging type, estrogen receptor status, grade, and comparative genomic hybridization. Breast Cancer Res Treat 2001; Abstract 235.

Fernandez A et al. Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl Med Commun 2001;22:361-6. Abstract

Fisher B et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16(8):2672-2685. Abstract

Fumoleau P et al. A randomized phase II study of 4 or 6 cycles of Adriamycin/Taxol (paclitaxel) as neoadjuvant treatment of breast cancer. Breast Cancer Res Treat 2001;Abstract 508.

Gianni L et al. Adjuvant and neoadjuvant treatment of breast cancer. Semin Oncol 2001;28:13-29. Abstract

Gomez H et al. A phase II study of neoadjuvant gemcitabine plus doxorubicin in stage IIIB breast cancer: A preliminary report. Semin Oncol 2001;28:57-61. Abstract

Haid A et al. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma? Cancer 2001;92:1080-4. Abstract

Hurley JE et al. High rate of axillary node clearance with neoadjuvant Herceptin, Taxotere, and Cisplatin in locally advanced and inflammatory breast cancer. Breast Cancer Res Treat 2001; Abstract 516.

Jackisch C et al. Dose-dense weekly (8 weeks) vs. sequential (24 weeks) neoadjuvant chemotherapy with adriamycin/cyclophosphamide and docetaxel in operable breast cancer (T2-3, N0-2, M0) - Interim analysis of the Geparduo trial. Breast Cancer Res Treat 2001; Abstract 509.

Jakesz R. Comparison of pre-vs.postoperative chemotherapy in breast cancer patients: Four-year results of Austrian Breast &Colorectal Study Group (ABCSG)Trial 7. Proc ASCO 2001; Abstract 125.

Julian TB et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg 2001;182:407-10. Abstract

Mamounas EP, Fisher B. Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol 2001;28:389-99. Abstract

Mathieu MC et al. Do biological markers expressed by invasive lobular carcinoma account for low response to neoadjuvant chemotherapy? Breast Cancer Res Treat 2001;Abstract 233.

McIntosh SA et al. Neoadjuvant chemotherapy for locally advanced breast cancer: Clinical and radiological response as predictors of local recurrence. Breast Cancer Res Treat 2001;Abstract 513.

Minton SE et al. A phase II neoadjuvant trial of sequential doxorubicin and docetaxel for the treatment of stage III breast cancer measuring signal transducers and activators of transcription (STAT) activation as a predictor of response to therapy. Breast Cancer Res Treat 2001;Abstract 514.

NSABP. The effect of primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: Preliminary results from NSABP Protocol B-27. Breast Cancer Res Treat 2001;Abstract 5.

Ostapenko VM et al. Neoadjuvant chemotherapy in combined treatment of stage II breast cancer patients. Breast Cancer Res Treat 2001;Abstract 517.

Petit T et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res 2001;7:1577-81. Abstract

Pienkowski TJ et al. Predictive value of HER-2, p53, bax, MIB-1 and hormonal receptors status in adjuvant treatment of breast cancer patients. Breast Cancer Res Treat 2001;Abstract 238.

Pronzato P et al. Thymidine labeling index analysis in early breast cancer patients randomized to receive perioperative chemotherapy. Oncology 2001;60:88-93. Abstract

Sanchez-Rovira P et al. HER2-status as a predictive factor for pathological complete response in primary breast cancer patients treated with gemcitabine-adriamycin-taxol as neoadjuvant treatment. Breast Cancer Res Treat 2001;Abstract 240.

Sartor CI et al. Low rate of ipsilateral breast tumor recurrence for patients with T3/T4 tumors treated with neoadjuvant chemotherapy followed by breast conserving therapy. Breast Cancer Res Treat 2001;Abstract 143.

Singletary SE. Neoadjuvant chemotherapy in the treatment of stage II and III breast cancer. Am J Surg 2001;182:341-6. Abstract

Smith IC, Miller ID. Issues involved in research into the neoadjuvant treatment of breast cancer. Anticancer Drugs 2001;12 Suppl 1:S25-9. Abstract

Smith IC et al. Current and potential chemotherapeutic agents used for induction chemotherapy in the treatment of breast cancer. Curr Pharm Des 2000;6(3):327-43. Abstract

Stebbing J J, Gaya A. The evidence-based use of induction chemotherapy in breast cancer. Breast Cancer 2001;8:23-37. Abstract

Stephens FO. Induction chemotherapy: To downgrade aggressive cancers to improve curability by surgery and/or radiotherapy. Eur J Surg Oncol 2001;27:672-88. Abstract

Symmans WF et al. RNA yield from needle biopsies for cDNA microarray analysis of breast cancer prior to neoadjuvant chemotherapy. Breast Cancer Res Treat 2001;Abstract 518.

Tafra L et al. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am J Surg 2001;182:312-5. Abstract

van der Hage JA et al. Improved survival after one course of perioperative chemotherapy in early breast cancer patients. Long-term results from the European Organization for Research and Treatment of Cancer (EORTC) Trial 10854. Eur J Cancer 2001;37:2184-93. Abstract

van der Hage JA et al. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224-37. Abstract

von Minckwitz G et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase IIb study. J Clin Oncol 2001;19:3506-15. Abstract

Back | Top of Page